Orthopedics giant Zimmer Biomet entered into a definitive agreement to acquire Embody, a company that makes collagen-based implants designed to heal soft tissue injuries. Zimmer Biomet pursued the deal to grow its sports medicine portfolio and gain entry into the high-growth rotator cuff augmentation submarket, an executive said.
Formus Labs is expecting to get the regulatory nod from the FDA to be able to sell its fully-automated 3D planning technology for joint replacement surgeries in the second quarter and has partnered with orthopedic surgery heavyweight for a global distribution program.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Early data showed that Zimmer Biomet’s MyMobility app yielded similar results to patients who received traditional care after knee surgery. Zimmer Biomet shared its findings from the randomized controlled clinical trial on Thursday.
Participants will use Zimmer Biomet mymobility's Apple Watch app as a digital interactive care plan to help guide them in surgery preparation, recovery and rehab tasks.
Zimmer Biomet pre-announced disappointing second-quarter results while also revealing that David Dvorak had stepped down as CEO, a move that some analysts feel was long needed.
The shift from volume to value is no where more apparent than in the orthopedics specialty where vendors that once obsessed over titanium and steel are now focusing on services to manage the bundled payment era.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
As the buzz around robotics grows, J&J 's DePuy Synthes is touting the clinical and economic evidence tied to its non-robotic knee platform to help hospitals navigate the bundled payments era, but will that sway them?
Zimmer Biomet just acquired a telerehab startup, RespondWell, to play in a different part of the bundle as it relates to the Comprehensive Care for Joint Replacement program for hip and knee replacements. Stryker is not interested in such technology.
The deal reflects Zimmer Biomet's interest in supporting value-based care through the company's Signature Solutions program to hospitals.
Zimmer Biomet wants to help hospitals use technology and other tools to maintain good patient outcomes and improve hospital efficiencies in a bid to stay relevant in the shift to value-based care.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
After dismissing robotics in orthopedics, Zimmer Biomet is jumping on the bandwagon.